Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Revance Therapeutics
(NQ:
RVNC
)
3.020
-0.140 (-4.43%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Revance Therapeutics
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Revance to Participate in Upcoming Virtual Healthcare Conferences
May 26, 2021
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Provides Update on DaxibotulinumtoxinA for Injection Pre-Approval Inspection
May 26, 2021
From
Revance Therapeutics, Inc.
Via
Business Wire
Recap: Revance Therapeutics Q1 Earnings
May 10, 2021
Shares of Revance Therapeutics (NASDAQ:RVNC) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 6.09% over the...
Via
Benzinga
Revance Reports First Quarter 2021 Financial Results, Provides Corporate Update
May 10, 2021
From
Revance Therapeutics, Inc.
Via
Business Wire
Earnings Scheduled For May 10, 2021
May 10, 2021
Companies Reporting Before The Bell • Revlon (NYSE:REV) is likely to report earnings for its first quarter. • Bluegreen Vacations (NYSE:BVH) is expected to report...
Via
Benzinga
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
May 09, 2021
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came...
Via
Benzinga
Exposures
COVID-19
Product Safety
Revance to Release First Quarter 2021 Financial Results on Monday, May 10, 2021
May 03, 2021
From
Revance Therapeutics, Inc.
Via
Business Wire
Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million Deal
May 01, 2021
CANbridge Pharma of Beijing acquired a global license to LogicBio’s adeno-associated virus sL65 in gene therapy candidates for Fabry and Pompe disease treatments. CANbridge will make a $10 million...
Via
Talk Markets
Revance to Showcase Clinical Findings at The Aesthetic Meeting 2021 that Supports DaxibotulinumtoxinA’s 24-Week Long Duration Profile Across Multiple Female Age Cohorts
April 27, 2021
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance Announces First Patient Enrolled for DaxibotulinumtoxinA in Glabellar Lines and Cervical Dystonia in China by Fosun Pharma
April 27, 2021
From
Revance Therapeutics, Inc.
Via
Business Wire
Revance to Present Data on DaxibotulinumtoxinA for Injection and Hyaluronic Acid Fillers at American Academy of Dermatology VMX Meeting 2021
April 23, 2021
From
Revance Therapeutics
Via
Business Wire
The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight
April 10, 2021
Contrary to the strength in the broader market, biotech stocks ended the week ending April 9 lower. The weakness partly reflected a preference for risky bets at the expense of...
Via
Benzinga
Exposures
Product Safety
Revance to Participate in the 20th Annual Needham Virtual Healthcare Conference
April 06, 2021
From
Revance Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
...
7
8
9
10
11
12
13
14
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.